One Year Glargine Treatment in CFRD Children and Adolescents

Federico II University20 enrolled

Overview

Glargine treatment can improve the clinical features in Cystic Fibrosis patients affected by glucose derangements

To evaluate the effect of glargine treatment on BMI, lung function, acute pulmonary infections and HbA1c in cystic fibrosis (CF) patients with different glucose derangements, eighty-seven patients were screened for glucose derangements with fasting hyperglycaemia or abnormalities at the oral glucose tolerance test. They were classified on the basis of a "gluco-score" ranging 0-5. Patients with gluco-score \> 1 were treated with glargine. We report on the results of the first 20 patients who completed 12 months of treatment. BMI z-score, forced expiratory volume in the first second (FEV1), number of acute lung infections in the previous year and HbA1c were the study outcomes.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Cystic Fibrosis Glucose Metabolism Disorders

Interventions

GlargineDRUG

Eligibility

Sex: ALLMin age: 3 YearsMax age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients affected by Cystic Fibrosis who had shown glucose derangements. Exclusion Criteria: * Patients with/without Cystic Fibrosis without glucose derangements.

Locations (1)

Deptm of Pediatrics Regional Cystic Fibrosis Center- University of Naples - Federico II

Naples, Naples, Italy

Outcomes

Primary Outcomes

Reduction of decline in pulmonary function measured as FEV1

Time frame: One year

Secondary Outcomes

Improvement of: Body Mass Index, Number of Lung Infections, HbA1c

Time frame: One Year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.